The p53 protein is the most studied tumor suppressor and the p53 pathway has been shown to mediate cellular stress responses that are disrupted when cancer develops. After DNA damage, p53 is activated as transcription factor to directly induce the expression of target genes involved in cell-cycle arrest, DNA repair, senescence and, importantly, apoptosis. Post-translational modifications of p53 are essential for the activation of p53 and for selection of target genes. The tumor suppressor homeodomain-interacting protein kinase-2 (HIPK2) is a crucial regulator of p53 apoptotic function by phosphorylating its N-terminal serine 46 (Ser46) and facilitating Lys382 acetylation at the C-terminus. HIPK2 is activated by numerous genotoxic agents and can be deregulated in tumors by several conditions including hypoxia. Recent findings suggest that HIPK2 active/inactive protein can affect p53 function in multiple and unexpected ways. This makes p53 as well as HIPK2 interesting targets for cancer therapy. Hence, understanding the role of HIPK2 as p53 activator may provide important insights in the process of tumor progression, and may also serve as the crucial point in the diagnostic and therapeutical aspects of cancer.
Introduction
The tumor suppressor protein, p53, is a transcription factor that has an essential role in guarding the cell in response to several stress signals through the induction of genes involved in growth arrest, apoptosis, senescence and DNA repair (Vazquez et al., 2008) . The p53 protein consists of 393 amino acids and is commonly divided into three functional domains: the acidic amino-terminal domain that is required for transcriptional activation (transactivation domain, TAD), the central core, which is sequence-specific DNA-binding domain and the carboxy-terminal end that contains the tetramerization domain, a nuclear export signal and nuclear localization signals and a C-terminal regulatory domain ( Figure 1a ). In normal cells, p53 is expressed at low level with short half-life that is controlled mainly by MDM2 (HDM2 in human and herein as MDM2) ubiquitin ligase and is therefore mostly silent. The inhibitory loop between p53 and MDM2 is interrupted in response to DNA damage when p53 is activated mainly at the post-translational level by a complex series of modifications including phosphorylation, acetylation and ubiquitination, involving the control of cell life and death (Bode and Dong, 2004) . Multiple molecular mechanisms contribute to the target selectivity of p53, and the choice of p53 between life and death may be dictated by its ability to switch on preferentially particular subsets of genes (Vousden and Liu, 2002) . For instance, covalent modifications of p53 may have a critical role in its target gene preference possibly through conformational changes, which directly alter its DNA-binding specificity. However, the activation of p53 is also influenced by a series of other interacting proteins. p53 is inactivated in human tumors by either point mutations that cluster in the p53 DNAbinding domain or by partial abrogation of signaling pathways or effector molecules that regulate p53 activity. Impairment of wild-type (wt) p53 function has a crucial role in tumor evolution by allowing evasion from p53-dependent responses. The restoration of p53 activity in established tumor cells is extremely helpful for intervention in cancer, as shown by several genetic studies (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007) . Those studies suggested that the reactivation of the p53 pathway in tumors has the potential to reduce tumor growth either in combination with other therapies or alone. Therefore, there is a growing interest in understanding the mechanisms of p53 inactivation and the therapeutic possibilities of reactivating dysfunctional p53 in cancers in order to halt tumor growth (Brown et al., 2009) . In this review, we will focus on the role of homeodomain-interacting protein kinase-2 (HIPK2) in p53 activation.
HIPK2 is a nuclear serine-threonine kinase originally identified to interact with the homeodomain transcription factor NK-3 and is a member of the HIPK family (numbered 1-4), which are highly conserved in vertebrates (Kim et al., 1998) . Murine HIPK2 structure, which is highly homologous to the human one, comprises an N-terminal region containing a sumoylation site (K25) and a kinase domain (K221), then a homeobox-interacting domain and a C-terminal region that includes a speckle-retention signal, a putative autoinhibitory domain and an ubiquitylation site (K1182) (Figure 1b) . HIPK2 is essentially a nuclear protein localized in the nuclear bodies and is prominently involved in two basic cellular functions: regulation of cell cycle/apoptosis and steering of transcription. These basic functions of HIPK2 may explain its reported role in other biological processes such as development and its potential function as tumor suppressor. However, the kinase domain of HIPK1, 2 and 3 shows 490% homology, suggesting, at least in part, functional redundancy. Indeed, mice knockout for either Hipk1 or Hipk2 alone are nearly normal (Kondo et al., 2003; Wiggins et al., 2004) , whereas the Hipk1/ Hipk2 double knockout embryos do not develop beyond 12.5 days postcoitus (Isono et al., 2006) . HIPK3 and HIPK4 members are, until now, the least characterized. On the other hand, HIPK2À/À and HIPK2 þ /À mice are tumor prone and develop skin tumors with the twostage carcinogenesis protocol, with high frequency, accompanied by lymphoid enhancer factor 1/b-cateninmediated cyclin D1 expression (Wei et al., 2007) .
Thus, HIPK2 forms a protein complex with b-catenin and lymphoid enhancer factor 1 and recruits another corepressor, namely, CtBP for cyclin D1 repression (Wei et al., 2007) . HIPK2 regulates gene expression by phosphorylation of transcription factors and accessory components on the transcription machinery or by recruitment of corepressor components and several extensive reviews have summarized these findings (Calzado et al., 2007; Rinaldo et al., 2007a) .
One of the most interesting HIPK2-interacting protein is oncosuppressor p53 that is phosphorylated by HIPK2 at Ser46 leading to activation of proapoptotic target genes by p53. HIPK2 can be activated by several types of stress, including ultraviolet, ionizing radiation and drugs, such as cisplatin (CDDP), adriamycin (ADR) and roscovitin (D 'Orazi et al., 2002; Hofmann et al., 2002; Di Stefano et al., 2004a; Dauth et al., 2007; Wesierska-Gadek et al., 2007) . On the other hand, few studies report that HIPK2 is inactivated in tumors by some mechanisms including hypoxia-driven proteasomal degradation that consequently also affect p53's function leading to chemoresistance and tumor progression (see below). For these reasons, HIPK2 protein is a novel biomarker in tumors and a promising target for anticancer therapies . In this study, we draw attention to the findings on HIPK2 regulation of p53, including phosphorylation, acetylation and conformation stability, with a focus on novel strategies to reactivate HIPK2 and therefore, p53 and to improve therapeutic efficacy across a broad range of human cancers.
HIPK2 phosphorylates p53 at Ser46 and mediates apoptosis
HIPK2 was identified by a yeast two-hybrid system as a p53-interacting protein (D 'Orazi et al., 2002; Hofmann et al., 2002) . HIPK2 binds to the C-terminal domain of p53 and specifically phosphorylates p53 at the NH 2 -terminal Ser46 for the p53-mediated transcriptional activation of proapoptotic factors such as p53AIP1, PIG3, Bax, Noxa, Puma and KILLER/DR5 (D 'Orazi et al., 2002; Di Stefano et al., 2004a; Pistritto et al., 2007) , as well as for the repression of the antiapoptotic factor galectin-3 (Cecchinelli et al., 2006) . Ser46 locates in the TAD 2 (TAD2, residues 43-63) of p53 that is necessary for apoptosis. Thus, deletion of the TAD2 abolishes this activity, and phosphorylation at both Ser46 and Thr55 enhances the binding of p62 and Tfb1 to p53, which have an important role in regulating p53-target genes activation (Di Lello et al., 2006) . The specific p53Ser46 phosphorylation is considered to be a sensor for DNA-damage intensity that induces a fine change of p53 conformation varying the p53 affinity for different promoters with a shift from cell-cycle-arrestrelated genes (that is, p21
Waf1 and MDM2) toward proapoptotic genes (that is, p53AIP1) (Oda et al., 2000; Mayo et al., 2005 HIPK2/p53 function in tumor suppression R Puca et al is also regulated by the prolyl-isomerase Pin1 that promotes efficient recruitment of p53 to its target promoters and by p53Lys382 acetylation mediated by p300. After phosphorylation of p53 at Ser46 triggered by either ultraviolet, etoposide or ADR treatments, Pin1 promotes p53 dissociation from iASPP, a p53-negative regulator (Zacchi et al., 2002; Mantovani et al., 2007) , thus linking p53 post-translational modifications with transcriptional activity. An important cofactor for HIPK2-induced p53Ser46 phosphorylation is the tumor suppressor protein promyelocytic leukemia (PML) (Moller et al., 2003a) . PML recruits a variety of enzymes and transcription factors in the nuclear bodies and has emerged as an important regulator of cell cycle, transcription, senescence and importantly apoptosis (Bernardi and Pandolfi 2007; Krieghoff-Henning and Hofmann, 2008) . Thus, the HIPK2-mediated p53 phosphorylation is impaired in PML À/À cells (Moller et al., 2003a) . Besides PML, other proteins function as cofactors for HIPK2-mediated p53Ser46 phosphorylation by binding to p53 and HIPK2. These include the PML-nuclear body components Sp100 (Moller et al., 2003b) and the death domain-associated protein Daxx (Li et al., 2007a) , the p53-inducible factor p53DINP1/ TP53INP1 (Okamura et al., 2001; Tomasini et al., 2003) and Axin (Rui et al., 2004) , a master scaffold for the regulation of the Wnt/b-catenin signaling pathway (Kikuchi, 1999; Peifer and Polakis, 2000) (Figure 2 ). Axin (amino acids 678-753) physically interacts with HIPK2 (amino acids 935-1050) as well as p53-activating HIPK2-mediated p53Ser46 phosphorylation and facilitates p53-dependent transcriptional activity and apoptosis (Rui et al., 2004) . The stimulatory effect of Axin on p53-dependent transcriptional activity is abrogated in the presence of kinase-inactive HIPK2 (K221R). The removal of the Axin-interacting domain from HIPK2 stimulates p53 transactivation even more dramatically than wt p53, suggesting that Axin physically occupies a putative autoinhibitory domain located in the C-terminus of HIPK2 (Rui et al., 2004) . The physiological relevance of the HIPK2 autoinhibitory domain was shown during the initiation of apoptosis. The induced p53 after DNA damage allows for caspase-mediated HIPK2 cleavage at positions 916 and 977 (Gresko et al., 2006) . This C-terminus truncated HIPK2 results in a hyperactive kinase, which potentiates p53Ser46 phosphorylation and activation of apoptosis. At later time points during ongoing apoptosis, the cleaved HIPK2 fragments are eliminated by further proteolytic degradation (Gresko et al., 2006) (Figure 2 ). The HIPK2 processing requires caspase-6, and caspase-resistant HIPK2 mutants induce apoptosis less efficiently than the wt (Gresko et al., 2006) . Caspase-6 is an established p53-target gene (MacLachlan and El-Deiry, 2002) , suggesting a tight regulation of HIPK2 in a p53-dependent manner. A similar mechanism, which is the elimination of a regulatory kinase by a p53-induced apoptotic program, is also seen for ERK2, which is inactivated in order to prevent ERK-mediated cell proliferation in the presence of activated p53 (Marchetti et al., 2004) . These regulatory loops to the p53 system ensure a highly integrated control of p53 activity. Furthermore, Axin can dictate p53-dependent cell-cycle arrest or apoptosis depending on the severity of genotoxic stress that allows distinct complexes formation of p53 with Pirh2, Tip60 and HIPK2 (Li et al., 2009) . Pirh2 is a gene regulated by p53 that encodes a RING-H2 domain-containing protein with intrinsic ubiquitin-protein ligase activity. Pirh2 physically interacts with p53 and promotes ubiquitination of p53 independently of MDM2 (Leng et al., 2003) . Tip60 induces p53 acetylation specifically at Lys120 (K120), within the DNA-binding domain, that is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest (Tang et al., 2006) . In nonseverely damaged cells (that is, 0.4 mM ADR), Pirh2 attenuates Axin-induced p53Ser46 phosphorylation independently of its E3 activity; thus, Pirh2 competes with HIPK2 for binding to Axin. Under lethal dose of genotoxic stress (that is, 2.5 mM ADR), ATM and ATR activate Tip60 that interacts with Axin and abrogates Pirh2-Axin binding, forming an Axin-Tip60-HIPK2-p53 complex that allows maximal p53 activation to trigger apoptosis (Li et al., 2009) . This underlines the critical roles of HIPK2 and Tip60 in the induction of apoptosis after lethal DNA damage. On the other hand, in nonseverely damaged cells, HIPK2 is cleared by p53-induced MDM2 E3 ubiquitin ligase, inhibiting apoptosis (Rinaldo et al., 2007b ) (see below). Finally, silencing of endogenous HIPK2 by antisense oligonucleotides or by RNA-interference strongly reduces p53Ser46 phosphorylation (whereas, for instance, Ser15 phosphorylation 
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Figure 2 Schematic representation of p53 apoptotic regulation by HIPK2. HIPK2 phosphorylates p53 at Ser46 to direct p53 transcription toward proapoptotic genes rather than cell cycle (p21) or p53 regulatory (MDM2) genes. Important cofactors for HIPK2-induced p53Ser46 phosphorylation (that is, PML, Daxx, Axin and so on) and p53 acetylation (that is, p300, TIP60), which efficiently induce apoptosis, are shown. The regulatory loop between p53 and HIPK2 leading to HIPK2 proteolysis during the termination phase of apoptosis, through p53-induced caspase-6, is shown.
HIPK2/p53 function in tumor suppression R Puca et al is not affected) and p53 apoptotic function, ultimately promoting cell resistance to drug-induced apoptosis (D 'Orazi et al., 2002; Di Stefano et al., 2004a) .
Interaction between HIPK2, p53 and MDM2
An important mechanism that regulates p53-apoptotic function involves MDM2 oncogene. The MDM2 protein is a negative regulator of p53 by means of its E3 ubiquitin ligase activity that targets p53 for proteasomal degradation (Haupt et al., 1997; Kubbutat et al., 1997) . The MDM2 gene is positively regulated by p53, thus defining an autoregulatory negative feedback loop (Harris and Levine, 2005) . This feedback loop, in which p53 upregulates MDM2 expression, whereas MDM2 downregulates p53 activity, is essential for restraining p53 function in nonstressed cells and probably for eliminating accumulated p53 after successful completion of DNA repair. Several studies have shown that DNA-damage-induced phosphorylation of serine and a threonine residues at the N-terminus contributes to p53 stability by preventing MDM2 from proteasomal degradation (Unger et al., 1992; Shieh et al., 1997) . In this regard, HIPK2-induced p53 phosphorylation changes the interaction between MDM2 and p53, prevents the MDM2-mediated cytoplasmic shuttling and ubiquitination of p53 in response to genotoxic agents and recovers the p53 apoptotic function (Di Stefano et al., 2004b) . Exogenous HIPK2 was shown to correlate with the reduction of MDM2 protein levels (Wang et al., 2001 ). This regulation is in line with the model showing that Ser46 phosphorylation determines p53 promoter selection toward the lowaffinity proapoptotic ones, impairing MDM2 transcription (Oda et al., 2000; Mayo et al., 2005) . Furthermore, HIPK2 and MDM2 can form a stable complex in vitro and in vivo and HIPK2 has been shown to phosphorylate MDM2 and to promote MDM2 proteasomal degradation also in a p53-independent manner (Di Stefano et al., 2005a) . However, whether HIPK2 directly or indirectly phosphorylates MDM2 in vivo to target it for proteasomal degradation remains to be elucidated. MDM2 is not only a p53 inhibitor but also contributes to modulate the p53-mediated biological outcomes (that is, cell-cycle arrest versus apoptosis) to diverse triggering signals by regulating HIPK2. In response to nonlethal, presumably reparable DNA damage, p53-activated MDM2 inhibits the p53 apoptotic pathway by targeting HIPK2 at residue Lys1182 for proteasomal degradation (Rinaldo et al., 2007b) . This suggest that MDM2 does not serve only as a p53 antagonist, rather, it can sometimes have an important role downstream of p53, helping it to adjust the biological outcome to the nature of the triggering signal (Shmueli and Oren, 2007) . Furthermore, by the use of small molecules that target MDM2-p53 interaction to reactive p53, a controlled regulation of HIPK2 has been proposed. Among those molecules, Nutlin-3 binds to MDM2 in the p53 pocket and inhibits p53 degradation (Vassilev et al., 2004) and mainly induces mitotic arrest, whereas RITA (reactivation of p53 and induction of tumor-cell apoptosis) blocks the p53-MDM2 physical interaction and activates the transcription of proapoptotic target genes (Issaeva et al., 2004) . Nutlin-3, which maintains MDM2 E3 ubiquitin ligase, downregulates HIPK2 expression impairing p53Ser46 apoptotic outcome, whereas RITA activates HIPK2 and p53Ser46 phosphorylation (Rinaldo et al, 2009 ). These findings suggest that the indirect effects exerted on HIPK2 in the presence of MDM2 antagonists should be taken in consideration when one follows the cell decision between mitotic arrest and apoptosis by reactivated p53.
Role of HIPK2 in p53 acetylation
Full activation of p53 transcriptional function also involves p53 acetylation by coactivators/histones acetyltransferases (HATs), which takes place specifically in the C-terminal regulatory regions surrounding the tetramerization domain (Gu and Roeder, 1997; Liu et al., 1999; Espinosa and Emerson, 2001 ) and facilitates the recruitment of HATs to p53-target promoters (Barlev et al., 2001 ). HIPK2 and CREB-binding protein (CBP)/ p300 show a mutual interaction and HIPK2-mediated phosphorylation of p53Ser46 is required for the CBPinduced p53 acetylation at Lys382 (Hofmann et al., 2002) . Covalent modifications of p53 may change target gene preference by imposing conformational changes in p53 that recognize different p53-responsive elements. In this regard, K373 and K382 are necessary for binding of p53 to low-affinity proapoptotic promoters (Knights et al., 2006) . Chromatin immunoprecipitation studies show that HIPK2 is necessary in vivo for efficient p300/ p53 corecruitment onto apoptotic promoters of p53AIP1 and Puma. Moreover, both p53 modifications at Ser46 and Lys382 are necessary for successful interaction of p53 with its target apoptotic promoters and for proapoptotic transcription (that is, Bax, Puma and Noxa target genes) (Puca et al., 2009a) . This is in line with the concept that efficient induction of proapoptotic genes requires p53 interaction with different cofactors (Vousden and Liu, 2002) . Moreover, as several kinases have been claimed to phosphorylate p53 at Ser46, including ATM , DNAdependent protein kinase (Komiyama et al., 2004) , protein kinase C d (Yoshida et al., 2006) and dualspecificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) (Taira et al., 2007) , the fact that only HIPK2 can drive Lys382 acetylation renders this kinase a unique and complex regulator of p53 apoptotic function (Figure 3) . One important finding that supports the relationship between HIPK2, p53 and p300 for p53 apoptotic function comes from a leukemogenesis model in which the oncogene CBFb-SMMHC attenuates the p53 apoptotic function in response to DNA damage (that is, g-irradiation and VP-16) (Britos-Bray et al., 1998). CBFb-SMMHC prevents p300 phosphorylation by sequestering HIPK2 in the cytoplasm (Wee et al., 2008) , which becomes the mechanistic explanation of the attenuation of the HIPK2/p53 apoptotic pathway in response to DNA damage.
A tight regulation of p53 acetylation in vivo also implies the involvement of deacetylases (Sakaguchi et al., 1998) . Lys382 of p53 is a substrate for the SirT1 (NAD-dependent histone deacetylase)-mediated deacetylation, which antagonizes p53-dependent transcriptional activation and apoptosis in response to DNA damage and oxidative stress (Luo et al., 2001 , Vaziri et al., 2001 . In agreement, the impairment of p53Lys382 acetylation in HIPK2 knockdown can be rescued only by the SirT1 inhibitor nicotinamide, whereas trichostatin A, the inhibitor of histone deacetylase complexes does not have effect. This finding suggests that HIPK2 may fine-tune the p53 acetylation/deacetylation balance by stimulating on one hand the corecruitment of p300 onto apoptotic promoters and on the other hand by inhibiting SirT1 deacetylase activity (Puca et al., 2009a) (Figure 3) . One possible mechanism involved in p53Lys382 deacetylation includes Nox1 upregulation in HIPK2 knockdown . Nox1 is a homolog of the catalytic subunit of the superoxidegenerating NADPH-oxidase, involved in tumor progression and reactive oxygen species production (Kamata, 2009 ). Nox1 inhibits p53Lys382 acetylation impairing p53 proapoptotic transcriptional activity. By the use of either small interfering RNAs (siRNAs) to target SirT1 or of the SirT1 inhibitor nicotinamide, Nox1-dependent inhibition of p53 transcriptional activity seems to be SirT1 dependent. Thus, Nox1 is unable to inhibit p53 transcriptional activity when coexpressed with a SirT1 deacetylase defective mutant (SirT1HY) . The delicate balance of the regulation of Lys382 acetylation for controlling p53 apoptotic activity was recently shown by the study of a new player in the field, namely, the zinc-finger transcription factor KLF15, which suppresses p53. It was shown that KLF15 inhibits the p300-dependent acetylation of Lys382 (Haldar et al., 2010) , in contrast to the effect of HIPK2 that supports the acetylation. In KLF15 deficiency, p53 is highly acetylated and overactivated, leading to life-threatening condition of heart failure and aneurysm through a mechanism of p53-dependent muscle cells apoptosis. KLF15-deficient mice can be rescued by p53 deletion or by p300 inhibition (Haldar et al., 2010) . Thus, apoptosis that is considered mainly in the context of tumors should be avoided in normal cell biology to prevent dangerous physiological outcome in normal tissues. This underscores the unique contribution of HIPK2 to the control of p53 expression and apoptotic activity and indicates why promoting p53 apoptosis is a complicated matter of life and death not only in cancer but also in normal cells.
Finally, a role of HIPK2 in p53 acetylation that does not induce apoptosis has also been reported. In response to nonsevere DNA damage, HIPK2 is required for PCAF-mediated acetylation of p53 at Lys320 and for p53-induced transcription of the cell cycle inhibitor p21
Waf1 (Di Stefano et al., 2005b) . As nonsevere DNA damage also induces MDM2 for HIPK2 proteasomal degradation (Rinaldo et al., 2007b) , altogether these findings suggest that different degree of DNA damage can activate HIPK2 and subsequently induce p53 posttranslational modifications to fine-tune p53 transcriptional activity and control cell life or death.
Role of HIPK2 in wt p53 protein conformation
The conformational stability is a central mechanism controlling p53 function. It has been shown that the zinc atom is important in stabilizing the DNA-binding domain structure of p53 (Cho et al., 1994) and for p53 DNA-binding activity in vitro and in vivo (Verhaegh et al., 1998) . As a proof of principle, some p53 mutations in cancers (for example, mutation C242S, H179R, C176F and R175H) that perturb the zincbinding site in p53 result in the loss of DNA binding (Joenger and Fersht, 2007) . Studies in vitro show that In the absence of HIPK2 (that binds p300 and stimulates p53/p300 corecruitment onto apoptotic target genes), Lys382 acetylation is inhibited and Ser46 phosphorylation alone is not sufficient to induce p53 apoptotic transcription. Reduced Lys382 acetylation in the absence of HIPK2 partly depends on SirT1 deacetylase activation.
HIPK2/p53 function in tumor suppression R Puca et al treatment of wt p53 with metal chelators results in removal of zinc and disruption of the tertiary structure with loss of sequence-specific DNA binding to the canonical p53-target sites (Hainaut and Milner, 1993; Verhaegh et al., 1998) . On the other hand, addition of zinc allows p53 folding into wt conformation (Meplan et al., 2000) . Zinc availability is controlled through metal transfer reactions mediated by metallothioneins, a class of small, cysteine-rich proteins that operate as intracellular buffers for Zn 2 þ and several other divalent metal ions (Cu 2 þ , Ca 2 þ ). In recent years, evidence has accumulated that these mechanisms may control p53 status in both physiological and pathological conditions and regulate the Zn 2 þ dependent folding of p53 in vitro (Meplan et al., 2000) . Stable knockdown of HIPK2 by siRNA leads to p53 misfolding, yielding a 'mutant-like' conformation, identified by conformation-sensitive antibodies, that strongly affects p53 DNA binding and wt p53 transcriptional activities (Puca et al., 2008a) (Figure 4 ). This effect is correlated with enhanced expression of metallothionein 2A thus, HIPK2 binds to the metallothionein 2A promoter in a corepressor complex along with histone deacetylase complex 1 (Puca et al., 2009b) . Interestingly, the p53 mutant-like conformation in HIPK2 knockdown is reverted either by zinc supplementation or by silencing of metallothionein 2A with siRNA resulting in restoration of p53 DNA-binding and wt p53 transcriptional activities, in vitro and in vivo (Puca et al., 2008a (Puca et al., , 2009b . These observations show that p53 folding requires a cellular environment in which the availability of zinc is tightly controlled and that HIPK2 is reasonably affecting pathways involved in zinc regulation. Moreover, they suggest that a long-lasting HIPK2 inhibition can profoundly affect p53 oncosuppressor activity, likely leading to tumor progression. As a proof of principle, a significant association between low expression of HIPK2 and poor outcome for patients with wt p53 tumors, but not with mutant p53, was found by bioinformatics analyses of colon cancer patients (Puca et al., 2008a) as well as of breast cancer patients (Givol D and D'Orazi G, unpublished results) .
Similarly to what seen in tumors, we recently found that the altered conformational state of p53 in tissues from patients with Alzheimer's disease depends on bamyloid-induced HIPK2 degradation and that is rescued by zinc (Lanni et al., 2010) .
HIPK2 inactivation in tumors and p53 dysfunction
Given the multifunctional role of HIPK2 in p53 regulation, it is legitimate to evaluate which condition(s) can affect HIPK2 function in tumors and what is the consequence on p53 activation. Very few studies report HIPK2 transcriptional downregulation, for instance in thyroid, breast (Pierantoni et al., 2002) and colorectal carcinoma specimens (D 'Orazi et al., 2006) , although these findings still need extended functional studies. Two missense mutations were identified in human acute myeloid leukemias (AMLs), which led to aberrant distribution of HIPK2 within the nucleus with impaired transcription by AML1 and p53 transcription factors (Li et al., 2007b) . However, in that study, HIPK2 was found mutated in a very small percentage (2 out of 130 cases) so that it is difficult to justify a connection with p53 inactivation. HIPK2 cytoplasmic localization, similarly to what seen in the leukemogenesis model (Britos-Bray et al., 1998; Wee et al., 2008) (see above), was found related to high-mobility group A1 (HMGA1) overexpression leading to inhibition of p53-mediated apoptosis (Pierantoni et al., 2007) . HMGA1 protein is frequently overexpressed in tumors and correlates strongly with cytoplasmic HIPK2 localization and low apoptotic index in wt p53-positive human breast cancer tissues (Pierantoni et al., 2007) . These data strengthen the role of HIPK2 as p53 activator as well as biomarker for tumor progression even in the absence of p53 mutations.
However, by contrast, few studies reported that HIPK2 can stimulate cell growth and correlate with tumor progression. In pilocytic astrocytoma, HIPK2 gene is frequently amplified (40-60%) and HIPK2 overexpression stimulates cell growth (Deshmukh et al., 2008) . Strong HIPK2 immunostaining in cervical cancer tissues was also hypothesized to correlate with tumor progression (Al-Beiti and Lu, 2008) . Unfortunately, neither of these studies investigated the relationship between HIPK2 expression and p53 response to chemotherapeutic drugs. Thus, we found that cisplatin treatment of chemoresistant 2008C13 cells does not induce the HIPK2/p53Ser46 apoptotic response despite HIPK2 upregulation at protein level, whereas exogenous HIPK2 is able to overcome chemoresistance and restore p53 apoptotic response to drug (Puca et al., 2008b) . These findings suggest that different mechanisms other than HIPK2 protein upregulation/expression, including Figure 4 Role of HIPK2 in p53 wild-type conformation. HIPK2 maintains p53 wild-type conformation to bind DNA at sequencespecific response elements (SREs) for wt p53 transcriptional activity. HIPK2 inhibition (that is, by small interfering RNA) induces p53 misfolding, partly through MT2A upregulation), leading to abrogation of p53 DNA-binding and of wt p53 transcriptional activity.
HIPK2/p53 function in tumor suppression R Puca et al post-translational modifications or protein-protein interaction may be involved in HIPK2 activation. Therefore, more studies are needed to unveil the HIPK2 protein regulation to better clarify the impact of the HIPK2 status on tumor progression and on the outcome of cancer therapy.
One important condition that inhibits HIPK2 and that can be widely translated in solid tumors in vivo is hypoxia. HIPK2 is downregulated by RING family ligase seven in absentia homolog-2 (Siah2) during hypoxia (Calzado et al., 2009a) . Siah-2 and HIPK2 show a mutual regulation including HIPK2-mediated Siah-2 phosphorylation at positions 26, 28 and 68, which weakens mutual binding between both the proteins and destabilizes its phosphorylated interaction partner. Hypoxic condition triggers increased HIPK2/ Siah-2 interaction, which occurs by a still unknown mechanism but that induces HIPK2 polyubiquitination (Calzado et al., 2009a) . Accordingly, hypoxia-induced HIPK2 elimination is markedly reduced in Siah-2-deficient cells. HIPK2 downregulation during hypoxia strongly reduces ADR-induced p53Ser46 phosphorylation, moreover, it allows the HIPK2 elimination from promoter-associated repressor complexes with induction of a substantial fraction of hypoxia-induced genes such as PDK1, TGFB3, CYP1B1 (cytochrome P450) (Calzado et al., 2009a) and hypoxia-induced factor (HIF)-1a (Nardinocchi et al., 2009) . Other ubiquitin ligases involved in HIPK2 downregulation may take place during hypoxia including WD40-repeat/SOCS box protein WSB-1 (Choi et al., 2008) , which is a novel predicted HIF1 target gene, as identified by an integrative genomic approach, upregulated upon hypoxia (Benita et al., 2009) ; and the RING family member Siah-1, originally identified along with Siah-2 as HIPK2-interacting protein (Winter et al., 2009; Calzado et al., 2009a) . As for WSB-1 and Siah-2, Siah-1 depletion by siRNA partially inhibits hypoxia-induced HIPK2 degradation (Moehlenbrink et al., 2010) . Interestingly, the p53-inducible Siah-1L protein downregulates HIPK2, suggesting an autoregulatory control of p53 response during hypoxia (Calzado et al., 2009b) similarly to that observed in MDM2 induction after nonsevere DNA damage (Rinaldo et al., 2007b) (Figure 5 ). In agreement, hypoxic condition by either low oxygen or chemical compound that mimics hypoxia (that is, cobalt chloride) induces p53-target MDM2 that promotes HIPK2 degradation. HIPK2 downregulation allows upregulation of the HIF-1a pathway and inhibition of the p53Ser46 in response to ADR, leading to chemoresistance, angiogenesis and tumor growth in vitro and in vivo (Nardinocchi et al., 2009) . On the other hand, the use of siRNA to target the hypoxia-induced MDM2 rescued p53Ser46 phosphorylation and apoptosis in response to drug (Nardinocchi et al., 2009) . HIPK2 inhibition during hypoxia is supposed to drive p53 inactivation also because of induction of p53 mutantlike conformation. Thus, zinc supplementation restores p53 apoptotic transcription of Noxa and Puma target genes in response to drug; however, it also counteracts hypoxia-induced HIPK2 downregulation (Nardinocchi et al., 2009) (Figure 6 ). The zinc-induced HIPK2 restoration during hypoxia partly depends on the inhibition of MDM2-induced proteasomal degradation (Nardinocchi L and D'Orazi G, unpublished results) , although the exact mechanisms underlying this regulation need to be further elucidated. Finally, by hypothesizing that hypoxic areas do exist inside a tumor, in which most likely p53 and HIPK2 are also inhibited, the therapeutic efficacy of zinc in combination with chemotherapy in vivo in a tumor xenografts model was evaluated. Indeed, zinc supplementation strongly inhibits tumor growth in response to ADR with concomitant increase of p53 apoptotic transcription (Nardinocchi et al., 2009) . These findings strongly suggest that HIPK2 function/dysfunction can severely influence wt p53 oncosuppressor activity also in vivo, although the role of hypoxia in HIPK2 inhibition in vivo needs further evaluation.
Perspective
It is not even 10 years since HIPK2 was firstly reported to induce p53 apoptotic activity through Ser46 phosphorylation. During that time, an increasing body of Figure 6 Schematic representation of the balance biological outcome after HIPK2/p53 activation/inhibition. (1) Genotoxic agents activate HIPK2/p53 apoptotic pathway; (2) hypoxia, through E3 ubiquitin ligases, triggers HIPK2 proteasomal degradation (Ub), inactivating p53 apoptotic response; (3) zinc counteracts the hypoxia-induced HIPK2 downregulation, restoring the p53 apoptotic pathway.
HIPK2/p53 function in tumor suppression R Puca et al scientific data has delineated additional molecular mechanisms of HIPK2-induced p53 regulation, as well as of other transcription factors that have a role during human cancer progression. Thus, knowledge of the HIPK2-activated pathways has proven useful in the wt p53 dysfunction in cancer cells as well as in tumor progression. Therefore, the assessment of an active/ inactive HIPK2 becomes mandatory to evaluate the degree of tumor progression or response to antitumoral therapies, and, in this regard, an effort should be taken to produce tools such as antibodies to detect in vivo HIPK2 expression and subcellular localization, as well as to develop small molecules aimed to reactivate HIPK2 in vivo. Currently, a promising way to reactivate hypoxia-inhibited HIPK2 by zinc has provided great opportunities for developing novel therapeutic strategies for human cancer with inactive wt p53 and/or HIPK2. A recent report established the existence of a hypoxic niche that regulates glioblastoma stem cells (Seidel et al., 2010 ) that contribute to glioma radioresistance and tumor repopulation (Bao et al., 2006) . Assuming that hypoxia inhibits HIPK2, it would be interesting to evaluate whether zinc can target glioma stem cells and restore HIPK2/p53 function in response to therapies. Although the efficacy of HIPK2-targeted therapies in human cancers is still to be established, the insights gained into reversible HIPK2 inactive/active disclose the use of HIPK2 as a possible predictive biomarker for tumor aggressiveness and suggest further examination about the potential use of zinc likely in combination with stress-inducing therapies, to promote tumor inhibition and restore wt p53 response to antitumor therapies.
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